Company Directory

Natural product-inspired small molecules for sexual and mental health

Kadence Bio is a clinical-stage biopharma company developing small molecule therapeutics for sexual and mental health. Its lead asset KH-001 is an on-demand oral treatment for premature ejaculation, developed from nature-inspired medicinal chemistry based on kanna plant alkaloids and optimised through standard drug development approaches. KH-001 completed Phase 1 safety studies in 2024 and is progressing to Phase 2 trials. A secondary pipeline targets mood disorders through novel neuropsychiatric compounds.

Small molecule drug discovery targeting rare genetic diseases and oncology

Tay Therapeutics is a drug discovery company developing targeted small molecule therapies for rare genetic diseases and cancer. Its platform uses stop codon read-through technology to restore production of functional proteins disrupted by premature stop codon mutations, with programmes targeting oncology, cystic fibrosis, Duchenne muscular dystrophy, and epidermolysis bullosa. The company previously discovered and out-licensed two BET inhibitor programmes to VYNE Therapeutics, which are advancing in clinical trials for immuno-inflammatory conditions.

Biodiversity-derived protein data and AI models for biological design

Basecamp Research is a London-based biotech company that collects biological samples from extreme environments across more than 26 countries, building a proprietary metagenomic database of over ten billion novel protein sequences from more than one million previously unrecorded species. This dataset trains large AI foundation models for designing novel proteins and genetic medicines. The company partners with pharmaceutical, biotechnology, and industrial organisations under ethically-sourced biodiversity agreements.

Global laboratory supplies and services distributor for life sciences

VWR International Ltd is the UK operating entity of Avantor, a global distributor of laboratory products, reagents, consumables, equipment, and services to the life science, biopharma, healthcare, and advanced technology industries. The company provides researchers, manufacturers, and quality teams with procurement solutions spanning chemicals, cell culture media, single-use assemblies, chromatography products, and laboratory instrumentation across research, development, and production settings.

Global viral vector CDMO for cell and gene therapy

Oxford Biomedica (OXB) is a global contract development and manufacturing organisation specialising in viral vectors for cell and gene therapy. The company provides lentiviral, adeno-associated virus (AAV), and adenoviral vector development and manufacturing services from early-stage process development through to commercial-scale GMP manufacture. OXB is headquartered in Oxford and operates manufacturing sites across Oxfordshire, France, and the United States.

Benchtop super-resolution microscopes for single-molecule biological imaging

Oxford Nanoimaging (ONI) is an Oxford-based manufacturer of compact super-resolution fluorescence microscopes and consumable application kits for life science research. Its instruments enable researchers to visualise individual proteins, DNA, RNA, viruses, and nanoparticles at 20 nanometre resolution without specialist infrastructure. Applications include drug target validation, extracellular vesicle characterisation, antibody research, and spatial cell biology. Customers span academic institutions and pharmaceutical and biotechnology companies worldwide.

Genomic diagnostics products for cytogenetics, oncology and rare disease

Oxford Gene Technology is a genomic diagnostics company developing and manufacturing hybridisation-based reagents and assays for clinical and research laboratories. Its product portfolio spans FISH probes, chromosomal microarrays and next-generation sequencing panels, enabling detection of chromosomal abnormalities and somatic mutations across haematological malignancies, solid tumours, cytogenetics and rare diseases. A FISH probe for KMT2A rearrangement in acute leukaemia received FDA De Novo classification as a companion diagnostic in 2024.

Global biopharma with UK manufacturing, commercial and clinical operations

MSD is a global biopharmaceutical company discovering, developing, manufacturing and marketing medicines and vaccines across oncology, infectious disease, immunology, cardiometabolic disease and animal health. Its UK operations span pharmaceutical manufacturing at Cramlington, Northumberland, which supplies medicines into the Merck global network, alongside commercial and clinical development functions headquartered at Moorgate, London, and an Animal Health division based in Milton Keynes. MSD conducts approximately 150 clinical studies in the UK annually.

Automated bioreactor platform for cell and gene therapy manufacturing

microfluidX is a UK instruments company developing automated bioprocessing platforms for cell and gene therapy research and manufacturing. Its core product is a microfluidics-based bioreactor system designed for parallel cell culture process development and scalable cell expansion. The platform integrates online process analytical tools and data analytics and is intended to support the development and manufacture of autologous cell and gene therapies from research scale through to clinical and commercial production.

Reference materials, genomics tools and measurement science for life sciences

LGC is a life science reagents and reference materials company providing analytical standards, genomics tools and measurement science services to the pharmaceutical, diagnostics, food safety and research sectors. Its portfolio spans certified reference substances, nucleic acid synthesis, genomic analysis reagents and proficiency testing schemes embedded in quality assurance workflows globally. LGC hosts the UK's National Measurement Laboratory for chemical and biological measurement and performs the statutory role of Government Chemist.

Global pharma company in immunology, vaccines, and oncology

GSK is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of medicines and vaccines. Its pipeline and portfolio span respiratory and immunology, oncology, HIV (through its specialist subsidiary ViiV Healthcare), and infectious diseases including vaccines. The company operates major UK sites including its global R&D hub at Stevenage Bioscience Catalyst, manufacturing facilities at Barnard Castle, Ware, and Montrose, and its global headquarters in London's Knowledge Quarter.

Clinical-stage antifungal drug developer targeting invasive fungal infections

F2G is a clinical-stage biopharmaceutical company developing novel antifungal therapies for life-threatening invasive fungal infections. The company discovered the orotomides, a new class of antifungal agents that selectively inhibit fungal dihydroorotate dehydrogenase, a mechanism of action distinct from all approved antifungals. Its lead compound, olorofim, is an oral agent in Phase 3 development for invasive aspergillosis and has received FDA Breakthrough Therapy Designation for multiple indications.